drugset
drugset / Trial / NCT05356858

An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients

NCT05356858 ↗

Phase 2 Terminated 6 enrolled Xuanwu Hospital, Beijing
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label study, to evaluate the efficacy and safety of a BTK inhibitor zanubrutinib in participants with NMOSDs.

Timeline

Start
2022-05-07
Primary completion
2024-02-24
Completion
2024-02-24

Outcome

Outcome not reported

Stopped (Enrollment): “Difficult in participant recruiting”

Drugs

EvaluationDrugModalityDoseRoute
Subject Zanubrutinib Small molecule 80 mg Oral

Indications

neuromyelitis optica